Back to GetFilings.com



Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended December 31, 2003

 

or

 

¨ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT

 

For the transition period from              to             

 

Commission File Number 1-15445

 


 

DRUGMAX, INC.,

(Formerly DrugMax.com, Inc.)

(Exact name of registrant as specified in its charter)

 


 

NEVADA   34-1755390

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

25400 US Highway 19 North, Suite 137, Clearwater, FL 33763

(Address of principal executive offices)

 

(727) 533-0431

(Registrant’s telephone number, including area code)

 


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    x  Yes    ¨  No

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12-b-2 of the Exchange Act.)    ¨  Yes    x  No.

 

As of February 13, 2004 there were 7,185,642 shares of common stock, par value $0.001 per share, outstanding.

 



Table of Contents

DRUGMAX, INC. AND SUBSIDIARIES

FORM 10-Q

FOR THE QUARTER ENDED DECEMBER 31, 2003

 

TABLE OF CONTENTS

 

     Page #

PART I FINANCIAL INFORMATION

    

Item 1. Financial Statements

    

Condensed Consolidated Balance Sheets
December 31, 2003 (unaudited) and March 31, 2003

   3

Condensed Consolidated Statements of Operations
Three and Nine Months Ended December 31, 2003 and December 31, 2002 (unaudited)

   4

Condensed Consolidated Statements of Cash Flows
Nine Months Ended December 31, 2003 and December 31, 2002 (unaudited)

   5

Notes to Condensed Consolidated Financial Statements (unaudited)

   7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

   13

Financial Condition, Liquidity and Capital Resources

   19

Item 3. Quantitative and Qualitative Disclosures About Market Risk

   19

Item 4. Controls and Procedures

   19

PART II OTHER INFORMATION

    

Item 1. Legal Proceedings

   20

Item 4. Submission of Matters to a Vote of Security Holders

   21

Item 6. Exhibits and Reports on Form 8-K

   22

Signature Page

   25

Exhibit 31.1 Certification of Principal Executive Officer Pursuant to Section 302

    

Exhibit 31.2 Certification of Principal Financial Officer Pursuant to Section 302

    

Exhibit 32.1 Certification Pursuant to Section 906

    

Exhibit 32.2 Certification Pursuant to Section 906

    

 

2


Table of Contents

PART I – FINANCIAL INFORMATION

 

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

DRUGMAX, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

     December 31, 2003

    March 31, 2003

 
     (Unaudited)        
ASSETS                 

Current assets:

                

Cash and cash equivalents

   $ 166,900     $ 161,489  

Restricted cash

     —         2,000,000  

Accounts receivable, net of allowance for doubtful accounts of $1,247,468 and $1,253,826

     13,624,445       11,339,842  

Inventory

     16,153,678       19,458,940  

Due from affiliates

     —         10,470  

Deferred income tax asset

     668,294       668,294  

Prepaid expenses and other current assets

     1,652,004       1,079,740  
    


 


Total current assets

     32,265,321       34,718,775  

Property and equipment, net

     1,163,268       767,550  

Goodwill

     13,105,000       13,105,000  

Patents and trademarks

     129,718       —    

Notes receivable

     496,172       625,329  

Stockholders notes receivable

     21,277       100,000  

Net deferred income tax asset - long-term

     749,336       749,336  

Deferred financing costs, net

     425,207       78,912  

Other assets

     135,202       95,660  

Deposits

     85,291       33,561  
    


 


Total assets

   $ 48,575,792     $ 50,274,123  
    


 


LIABILITIES AND STOCKHOLDERS’ EQUITY                 

Current liabilities:

                

Accounts payable

   $ 9,586,174     $ 14,619,341  

Accrued expenses and other current liabilities

     350,202       415,065  

Credit line payable

     19,857,960       15,943,619  

Current portion of long-term liabilities

     215,632       470,176  

Due to affiliates

     —         4,377  
    


 


Total current liabilities

     30,009,968       31,452,578  

Long-term debt and capital leases

     184,073       35,847  

Other long-term liabilities

     —         501,561  
    


 


Total liabilities

     30,194,041       31,989,986  

Stockholders’ equity:

                

Preferred stock, $.001 par value, 2,000,000 shares authorized; no preferred shares issued or outstanding

     —         —    

Common stock, $.001 par value; 24,000,000 shares authorized; 7,178,976 shares issued and outstanding

     7,177       7,120  

Additional paid-in capital

     41,058,727       40,967,355  

Accumulated deficit

     (22,684,153 )     (22,690,338 )
    


 


Total stockholders’ equity

     18,381,751       18,284,137  
    


 


Total liabilities and stockholders’ equity

   $ 48,575,792     $ 50,274,123  
    


 


 

See accompanying notes to condensed consolidated financial statements.

 

3


Table of Contents

DRUGMAX, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

     For the Three
Months Ended
December 31, 2003


    For the Three
Months Ended
December 31, 2002


    For the Nine
Months Ended
December 31, 2003


    For the Nine
Months Ended
December 31, 2002


 

Revenues

   $ 50,245,129     $ 85,233,822     $ 171,093,405     $ 222,073,763  

Cost of goods sold

     48,177,875       83,350,640       164,903,388       215,929,273  
    


 


 


 


Gross profit

     2,067,254       1,883,182       6,190,017       6,144,490  

Selling, general and administrative expenses

     1,742,947       1,596,674       5,305,999       5,972,536  

Amortization expense

     —         —         —         18,000  

Depreciation expense

     61,325       72,517       167,791       220,048  

Goodwill impairment loss

     —         —         —         12,468,212  
    


 


 


 


Total operating expenses

     1,804,272       1,669,191       5,473,790       18,678,796  
    


 


 


 


Operating income (loss)

     262,982       213,991       716,227       (12,534,306 )
    


 


 


 


Other income (expense)

                                

Interest income

     8,979       33,045       27,514       72,659  

Other income

     2,562       14,413       459,595       39,408  

Interest expense

     (269,402 )     (226,263 )     (1,197,151 )     (806,583 )
    


 


 


 


Total other income (expense)

     (257,861 )     (178,805 )     (710,042 )     (694,516 )
    


 


 


 


Income (loss) before income tax provision and minority interest

     5,121       35,186       6,185       (13,228,822 )

Income tax provision

     —         (24,853 )     —         368,935  

Minority interest

     2,162       —         2,162       —    
    


 


 


 


Net income (loss)

   $ 7,283     $ 10,333     $ 8,347     $ (12,859,887 )
    


 


 


 


Net income (loss) per common share - basic

   $ 0.00     $ 0.00     $ 0.00     $ (1.81 )
    


 


 


 


Net income (loss) per common share - diluted

   $ 0.00     $ 0.00     $ 0.00     $ (1.81 )
    


 


 


 


Weighted average shares outstanding - basic

     7,178,976       7,160,938       7,160,938       7,119,172  
    


 


 


 


Weighted average shares outstanding - diluted

     7,388,704       7,281,265       7,276,983       7,119,172  
    


 


 


 


 

See accompanying notes to condensed consolidated financial statements.

 

4


Table of Contents

DRUGMAX, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

     For the Nine
Months Ended
December 31, 2003


    For the Nine
Months Ended
December 31, 2002


 

Cash flows from operating activities:

                

Net income (loss)

   $ 8,347     $ (12,859,887 )

Adjustments to reconcile net income (loss) to net cash used in operating activities:

                

Amortization of financing costs charged to interest expense

     190,305       98,961  

Depreciation and amortization

     167,791       238,048  

Minority interest

     (2,162 )     —    

Goodwill impairment loss and intangible assets charge

     —         12,468,212  

Bad debt expense

     —         908,769  

Forgiveness of liability

     (501,561 )     —    

Loss on disposal of assets

     2,227       1,121  

Increase in net deferred income tax asset

     —         (369,135 )

Changes in operating assets and liabilities, net of acquisition:

                

Accounts receivable, net

     (2,290,149 )     (3,848,399 )

Inventory

     3,529,905       2,787,821  

Due from affiliates

     10,470       593  

Prepaid expense and other current assets

     (580,744 )     (1,060,307 )

Other assets

     8,525       2,780  

Patents and trademarks

     (3,034 )     —    

Shareholder notes receivable

     78,723       —    

Notes receivable

     129,157       135,833  

Deposits

     (42,400 )     (4,608 )

Accounts payable

     (5,630,596 )     480,383  

Accrued expenses and other current liabilities

     (79,994 )     234,020  
    


 


Net cash used in operating activities

     (5,005,190 )     (785,795 )
    


 


Cash flows from investing activities:

                

Purchases of property and equipment

     (248,120 )     (36,159 )

Proceeds from sale of property and equipment

     —         2,756  

Cash paid for acquisition of Avery

     (34,071 )     —    
    


 


Net cash used in investing activities

     (282,191 )     (33,403 )